FK778

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

BK Polyomavirus

Conditions

BK Polyomavirus, Kidney Diseases

Trial Timeline

Jan 1, 2005 → Aug 1, 2006

NCT ID

NCT00104338

About FK778

FK778 is a phase 2 stage product being developed by Astellas Pharma for BK Polyomavirus. The current trial status is terminated. This product is registered under clinical trial identifier NCT00104338. Target conditions include BK Polyomavirus, Kidney Diseases.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00104338	Phase 2	Terminated	Jan 1, 2005	Aug 1, 2006	BK Polyomavirus
NCT00282230	Phase 2	Terminated	Nov 1, 2003	Oct 1, 2005	Kidney Transplantation
NCT00189735	Phase 2	Completed	Sep 1, 2003	Oct 1, 2005	Kidney Transplantation
NCT00451932	Phase 2	Completed	Oct 1, 2002	Sep 1, 2005	Liver Transplantation

Competing Products

1 competing product in BK Polyomavirus

See all competitors

Product	Company	Stage	Hype Score
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus	Astellas Pharma	Approved	85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved